Company Profile
The company was established in April 2021. St. Ann Biomedicine has a number of novel patents and antibody technology platforms, and has assembled a number of domestic and foreign professional R&D teams with PhDs and master's degrees as well as a consultant group with medical backgrounds. With the best cancer treatment strategy for patients as the core, Committed to the development of novel and effective multi-specific antibody drugs and nucleic acid therapeutic drugs.